Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) gapped up before the market opened on Wednesday following insider buying activity. The stock had previously closed at $6.95, but opened at $7.44. Immunome shares last traded at $7.26, with a volume of 247,799 shares trading hands.
Specifically, CEO Clay B. Siegall acquired 137,100 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $7.29 per share, with a total value of $999,459.00. Following the acquisition, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CTO Philip Tsai purchased 12,300 shares of the business's stock in a transaction on Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, with a total value of $103,566.00. Following the acquisition, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This represents a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In other news, Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction dated Monday, March 24th. The shares were acquired at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares in the company, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Analyst Upgrades and Downgrades
IMNM has been the topic of a number of research analyst reports. Stephens restated an "overweight" rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 target price for the company. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Finally, Wedbush restated an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has a consensus rating of "Buy" and a consensus target price of $25.50.
Check Out Our Latest Stock Analysis on Immunome
Immunome Stock Down 4.0 %
The firm has a fifty day moving average of $9.50 and a 200-day moving average of $11.31. The firm has a market cap of $607.79 million, a P/E ratio of -0.86 and a beta of 1.93.
Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Sell-side analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.
Institutional Trading of Immunome
Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in Immunome during the fourth quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome during the 4th quarter worth approximately $75,000. AlphaQuest LLC grew its holdings in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its holdings in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Immunome in the fourth quarter valued at approximately $95,000. Institutional investors own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Further Reading
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
